Abstract
The purpose of this study was to investigate the possible effects of pioglitazone on the pharmacokinetics of nifedipine and its main metabolite, dehydronifedipine, in rats. The effects of pioglitazone on P-glycoprotein (P-gp) and cytochrome P450 (CYP)3A4 activities were also evaluated. Nifedipine was mainly metabolized by CYP3A4. The pharmacokinetic parameters of nifedipine and dehydronifedipine were determined after oral and intravenous administrations of nifedipine to rats in the presence and absence of pioglitazone (0.3 and 1.0 mg/kg). Pioglitazone inhibited the CYP3A4 enzyme activity in a concentration-dependent manner. Inhibitory concentration (IC50) was 12.1 μM. In addition, pioglitazone significantly increased the cellular accumulation of rhodamine-123 in MCF-7/ADR cells overexpressing P-gp. The areas under the plasma concentration–time curve (AUC0–∞) and the peak plasma concentration (C max) of nifedipine were significantly increased by 52.1 and 59.1 %, respectively, in the presence of pioglitazone (1.0 mg/kg) compared with control group. The total body clearance (CL/F) of nifedipine was significantly (1.0 mg/kg) decreased by pioglitazone (35.8 %). Consequently, the absolute bioavailability (AB) of nifedipine in the presence of pioglitazone (1.0 mg/kg) was significantly higher (25.3 %) than that of the control. The metabolite–parent AUC ratio (MR) in the presence of pioglitazone (1.0 mg/kg) significantly decreased (23.9 %) compared to that of the control group. The increased bioavailability of nifedipine in the presence of pioglitazone may be due to an inhibition of the P-gp-mediated efflux transporter in the small intestine and to the inhibition of the metabolism by inhibition of CYP3A4 in the small intestine and/or the liver, and/or to a reduction of CL/F of nifedipine by pioglitazone.
Similar content being viewed by others
References
Benet LZ, Cummins CL, Wu CY (2003) Transporter–enzyme interactions: implications for predicting drug–drug interactions from in vitro data. Curr Drug Metab 4:393–398
Blackshear JL, Orlandi C, Williams GH, Hollenberg NK (1986) The renal response to diltiazem and nifedipine: comparison with nitroprusside. J Cardiovasc Pharmacol 8:37–43
Bogaards JJ, Bertrand M, Jackson P, Oudshoorn MJ, Weaver RJ, van Bladeren PJ, Walther B (2000) Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 30:1131–1152
Chilcott J, Tappenden P, Jones ML, Wight JP (2001) A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther 23:1792–1823
Choi DH, Li C, Choi JS (2009) Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats. Eur J Drug Metab Pharmacokinet 34:163–168
Choi JS, Choi JS, Choi DH (2014) Effects of licocharcone A on the bioavailability and pharmacokinetics of nifedipine in rats: possible role of intestinal CYP3A4 and P-gp inhibition by licochalcone A. Biopharm Drug Dispos 35:382–390
Cordon-Cardo C, O’Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at bloodbrain barrier sites. Proc Natl Acad Sci 86:695–698
Crespi CL, Miller VP, Penman BW (1997) Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem 248:188–190
Cummins CL, Jacobsen W, Benet LZ (2002) Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 300:1036–1045
Doherty MM, Charman WN (2002) The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? Clin Pharmacokinet 41:235–253
Dorababu M, Nishimura A, Prabha T, Naruhashi K, Sugioka N, Takada K, Shibata N (2009) Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. Biomed Pharmacother 63:697–702
Dresser GK, Spence JD, Bailey DG (2000) Pharmacokinetic–pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38:41–57
Funaki T, Soons PA, Guengerich FP, Breimer DD (1989) In vivo oxidative cleavage of a pyridine-carboxylic acid ester metabolite of nifedipine. Biochem Pharmacol 38:4213–4216
Grundy JS, Kherani R, Foster RT (1994) Sensitive high-performance liquid chromatographic assay for nifedipine in human plasma utilizing ultraviolet detection. J Chromatogr B Biomed Appl 654:146–151
Hamann SR, Piascik MT, McAllister RG Jr (1986) Aspects of the clinical pharmacology of nifedipine, a dihydropyridine calcium-entry antagonist. Biopharm Drug Dispos 7:1–10
Han CY, Cho KB, Choi HS, Han HK, Kang KW (2008) Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells. Carcinogenesis 29:1837–1844
He F, Bi HC, Xie ZY, Zuo Z, Li JK, Li X, Zhao LZ, Chen X, Huang M (2007) Rapid determination of six metabolites from multiple cytochrome P450 probe substrates in human liver microsome by liquid chromatography/mass spectrometry: application to high-throughput inhibition screening of terpenoids. Rapid Commun Mass Spectrom 21:635–643
Hong SP, Yang JS, Han JY, Ha SI, Chung JW, Koh YY, Chang KS, Choi DH (2011) Effects of lovastatin on the pharmacokinetics of diltiazem and its metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin. J Pharm Pharmacol 63:129–135
Kajosaari LI, Jaakkola T, Neuvonen PJ, Backman JT (2006) Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. Eur J Clin Pharmacol 62:217–223
Kelly PA, Wang H, Napoli KL, Kahan BD, Strobel HW (1999) Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4. Eur J Drug Metab Pharmacokinet 24:321–328
Kuroha M, Kayaba H, Kishimoto S, Khalil WF, Shimoda M, Kokue E (2002) Effect of oral ketoconazole on first-pass effect of nifedipine after oral administration in dogs. J Pharm Sci 91:868–873
Leveque D, Jehl F (1995) P-glycoprotein and pharmacokinetics. Anticancer Res 15:231–336
Lewis DFV (1996) Cytochrome P450. Substrate specificity and metabolism. In: Cytochromes P450. Structure, function, and mechanism. Taylor & Francis, Bristol, p 123
Lin JH, Chiba M, Baillie TA (1999) Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 51:135–158
Nishimura A, Fujimura M, Hasengawa F, Shibata N (2010) pharmacokinetic interaction between nifedipine and Coenzyme Q10. J Health Sci 56:310–320
Relling MV (1996) Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs? Ther Drug Monit 18:350–356
Rendic S, Di Carlo FJ (1997) Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29:413–580
Sahi J, Black CB, Hamilton GA, Zheng X, Jolley S, Rose KA, Gilbert D, LeCluyse EL, Sinz MW (2003) Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos 31:439–446
Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–423
Sorkin EM, Clissold SP, Brogden RN (1985) Nifedipine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders. Drugs 30:182–274
Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsuruo T, Itoyama S, Mori S (1988) Tissue distribution of P-glycoprotein encoded by a multidrug resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res 48:1926–1929
Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci 84:7735–7738
Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1989) Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 37:159–164
Wacher VJ, Wu CY, Benet LZ (1995) Overlapping substrate specificites and tissues distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129–134
Walsky RL, Gaman EA, Obach RS (2005) Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol 45:68–78
Wang Y, Zou MJ, Zhao N, Ren JG, Zhou H, Cheng G (2011) Effect of diallyl trisulfide on the pharmacokinetics of nifedipine in rats. J Food Sci 76:30–34
Watkins PB (1994) Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4:171–184
Yang SH, Choi JS, Choi DH (2011) Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. Pharmacology 88:1–9
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Choi, JS., Choi, I. & Choi, DH. Effects of pioglitazone on the pharmacokinetics of nifedipine and its main metabolite, dehydronifedipine, in rats. Eur J Drug Metab Pharmacokinet 41, 231–238 (2016). https://doi.org/10.1007/s13318-014-0249-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13318-014-0249-y